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ABSTRACT 
An autoaggression graft-versus-host (GVHD)-like syndrome or engraftment syndrome (ES) presenting with skin 
rash, fever, and other clinical findings can accompany the early phase of engraftment after autologous peripheral 
blood stem cell (PBSC)/bone marrow (BM) transplantation. Because ES was suggested to be analogous to GVI-ID, 
we have investigated whether ES was associated with any graft-versus-tttmor effect hat would affect disease pro- 
gression and survival in breast cancer patients. Eighty-five consecutive patients who received BM/PBSC transplan- 
tation for breast cancer (stages H-IV) between July 1991 and July 1997 with minimum 2-year follow-up were studied. 
Median follow-up time was 892 days (range, 106-2913 days). Thirty-three patients (39%) developed ES. The inci- 
dence of relapse/progressive disease for the whole cohort was 61% and was similar in patients who developed ES 
compared with those who did not. However, there was an increased rate of mortality observed among the patients 
who had developed ES versus those who had not, although it was statistically not significant, (52% versus 31%, 
respectively; log rank, P = .08). Increased mortality rates due to disease progression were seen i all patients with 
ES regardless of their disease stage. In relapsed patients, median survival time after transplantation was 586 days for 
those with ES versus 847 days for those without ES, and the mortality rate was 85% (17/20) versus 51% (16/31) (P = 
.008) for those with or without ES, respectively. Visceral (lung, liver, brain, adrenal) or multiple-site relapses were 
observed in 85% of patients with ES versus 52% without ES (P = .01). In conclusion, whereas there was no effect of 
ES on relapse rate, a surprisingly significant increase in disease-related mortality rates among relapsed breast cancer 
patients with ES was found. Thus, patients with ES should be considered for close follow-up and further therapy 
posttransplantation. 
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INTRODUCTION 
High-dose chemotherapy followed by autologous bone 
marrow transplantation (BMT) or peripheral blood stem cell 
transplantation (PBSCT) has been used for treatment of var- 
ious hematological nd nonhematological malignancies. 
Relapse after autologous transplantation remains the major 
cause of morbidity and mortality after these treatments [1]. 
Graft-versus-host disease (GVHD) is a complication of allo- 
geneic BMT and is thought o be the response of donor lym- 
phocytes against foreign histocompatibility antigens of the 
recipient [2]. A syndrome that clinically resembles GVHD 
has been reported in up to 10% of patients following autolo- 
gous BMT [3-5]. The graft-versus-leukemia (GV-L) and 
graft -versus-tumor (GVT)  effects are well-described 
immunologic responses that contribute substantially to the 
curative capacity of allogeneic BMT above that produced by 
the high-dose preparative regimens in leukemia and lym- 
phoma patients [6-8]. Relapse rates were shown to be higher 
in patients with hematological malignancies who receive 
T-cell-depleted allogeneic [9], autologous, or syngeneic 
marrows compared with those receiving unmanipulated allo- 
geneic transplants [10,11]. Studies aiming at inducing 
GVHD after autologous stem cell transplantation have been 
conducted to evaluate GVHD's potential antitumor activity 
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Table I .  Patient Characteristics 
No. o f  pat ients 84 
Age, median (range), y 46 (20-64) 
Follow-up, median (range), d 870 (106-2913) 
Disease stage, n 
II I I  
III 28 
IV 45 
Stem cell source, n 
Peripheral blood stem cells 67 
Bone marrow/peripheral blood stem cells 17 
No.  o f  mononuclear cells infused, 6, I 0 (0.88-14. I)  
median (range) x l08/kg 
against various malignancies, including lymphoma, multiple 
myeloma, acute myeloid leukemia, and breast cancer. 
Cyclosporin, [12-14], interferon I [15], and interferon cz 
[16,17] have all been used to facilitate the development of 
autologous GVHD with limited or no success. 
Engraftment syndrome (ES), also known as autoaggres- 
sion syndrome, is a well-described syndrome consisting of 
development of skin rash, noninfectious fever, and other 
clinical findings including platelet refractoriness and 
pulmonary symptoms (hypoxia, pulmonary alveolar hemor- 
rhage) at the time of hematological recovery and engraft- 
ment after autQlogous BMT [18-21]. These manifestations, 
as well as histological features of GVHD on skin biopsies, 
have led us and others to suggest hat ES is analogous to 
autologous GVHD [18,19]. ES has been noted to occur 
with greater frequency in breast cancer patients [18]. There- 
fore, in this study, we investigated whether development of
ES is associated with any GVT effect, which would be 
reflected in lower relapse and mortality rates after autolo- 
gous stem cell transplantation i  breast cancer patients. 
PATIENTS AND METHODS 
Study Population 
Retrospective data were collected by chart review of 
85 consecutive patients with breast cancer who underwent 
high-dose chemotherapy followed by autologous tem cell 
transplantation. All patients were treated in our institution 
between July 1991 and July 1997. Of these 85 patients, 
1 patient died on day 41 due to pulmonary toxicity (pul- 
monary alveolar hemorrhage) and was excluded from the 
analysis because the study included only patients with 2-year 
minimum follow-up. Thus, patients undergoing transplan- 
tation within the last 2 years were also excluded. Table 1 
shows patient characteristics. Median follow-up of the 
patients was 870 days (range, 106-2913 days). Median age 
was 46 years (range, 20-64 years). M1 patients had staging 
work-ups prior to transplantation, including computed 
tomographic (CT) scans of the chest, abdomen, and pelvis; 
CT scan or magnetic resonance imaging of the brain; bone 
scans; and BM biopsies. Disease stages at the time of trans- 
plantation were as follows: 11 patients in stage II, 28 in stage 
III, and 45 in stage Y~. Other data were collected regarding 
prior therapy (characterized by number of prior treatments), 
stem cell dose, time to relapse, pattern of relapse, mortality, 
and overall survival. M1 patients were treated with the same 
conditioning regimen (STAMP V), which included cyclo- 
phosphamide, 6000 rag/m2; carboplatin, 800 mg/m2; and 
thiotepa 500 rag/m2; all given by continuous infusion over 
96 hours. M1 patients who suffered posttransplantation 
relapse received standard therapy. 
Stem Cell Harvest and Transplantation 
PBSC mobilization was performed using granulocyte 
colony-stimulating factor (G-CSF) alone (10 ~tg/kg) or 
chemotherapy and G-CSF (5 Bg/kg). Cyclophosphamide, 
2 gm/m 2, was used for chemotherapy mobilization. G-CSF 
was administered subcutaneously starting 48 hours after the 
administration of priming chemotherapy and continued 
until completion of apheresis. Patients underwent 16- to 20-L 
leukapheresis using the Cobe Spectra blood cell separator 
(Cobe Laboratories, Lakewood, CO). Median cell dose 
infused was 6.1 x 108 mononnclear cells (MNCs)/kg (range, 
0.88-14.1 x 108 MNCs/kg). The median dose of CD34 + 
cells infused (data available for 34 patients only) was 3.33 • 
106/kg body wt (range, 1.01-7.27 x 106/kg body wt). Seven- 
teen patients received BM or both BM and PBSCs, and the 
remainder (67 patients) received only PBSCs. 
Engraftment Syndrome 
The autoaggression syndrome or ES was defined as pre- 
viously reported [18]. Typically, the syndrome appears 
approximately at the time of engraftment after autologous 
stem cell transplantation, usually includes maculopapular 
rash and noninfectious fever (up to 40~ and may also 
include thrombocytopenia with platelet ransfusion refrac- 
toriness, diarrhea, and diffuse pulmonary infiltrates with 
shortness of breath and hypoxemia [18-21]. Skin biopsies 
may show changes typical of acute GVHD [18]. The sever- 
ity of the syndrome varies, and sometimes it resolves ponta- 
neously. Patients with persistent fever and worsening rash or 
any other manifestations responded to treatment with 
methylprednisolone, I mg/kg per day, followed by a quick 
taper over 10 to 14 days with resolution of symptoms. In 
most patients, more than 50% of their body surface was 
covered with an erythematous maculopapular rash. Patients 
who developed pulmonary symptoms and hypoxia under- 
went bronchoscopy to rule out infectious etiology and were 
treated with high-dose methylprednisolone as previously 
described [18]. All occurrences of fever were investigated to 
rule out infection, using routine blood and urine cultures, 
chest x-rays, and any other studies indicated after physical 
examination. G-CSF was discontinued upon appearance of 
ES and any evidence of granulocyte recovery. 
Outcome and Statistical Analysis 
Patients who developed symptoms uggestive of ES 
were identified and compared with those who did not have 
ES. The relapse and survival rates were compared between 
the 2 groups (with or without ES) using the Fisher exact 
test. Overall survival rate was compared by time-to-event 
analysis using the Kaplan-Meier method. Statistical software 
(Statsoft, Groningen, the Netherlands) was used for analy- 
sis. The site of relapse (visceral versus nonvisceral) was also 
compared for both groups using the Fisher exact test. In 
order to investigate whether ES is an independent risk 
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Table 2. Overall Relapse Rate for Breast Cancer Patients After Autologous 
Transplantation 
Patients With 
Relapse/Progressive 
Disease Stage All Patients Disease, n (%) 
II i l 2 (I 8) 
ill 28 i l (39) 
iV 45 38 (84) 
Total 84 51 (61 ) 
factor for bad outcome, univariate as well as multivariate 
analyses were conducted using Cox Regression model SAS 
software version 6 (SAS Institute Inc, Cary, NC). Variables 
were included on an a priori basis, such as estrogen receptor 
(ER) status, the presence of visceral metastases at the time of 
transplantation, prior therapy, and others. We performed 
both a forward-stepping aswell as best-possible-subsets 
analysis for the regression modeling. 
RESULTS 
Pat ients  Wi th  ES 
Thirty-three patients (39%) developed ES. The manifes- 
tations were maeulopapular rash (n = 29) involving the body 
and extremities and temperature elevation (up to 40~ 
within 1 to 2 days after an increase in leukocyte count from a 
nadir of 100 to 200/~tL (n = 31) without evidence of infec- 
tion. Twenty-three ofthese patients with a persistent fever of 
>38.5~ and worsening itchy rash required treatment with 
methylprednisolone at 1 mg/kg per day for 3 days, followed 
by quick taper over 2 weeks with resolution of symptoms. 
Three patients had pulmonary alveolar hemorrhages in addi- 
tion to skin rash and high fever, and responded to high-dose 
methylprednisolone. None of the patients died from ES, and 
the response to steroids was usually dramatic within 
24 hours. There was no effect of CD34 + stem cell dose on 
development of ES. Data available for 34 patients howed 
median CD34 + stem cell doses of 3.0 • 106/kg versus 3.62 • 
106/kg in patients with and without ES, respectively. 
Ef fec t  o f  ES on  Re lapse  Rates  A f te r  Auto logous  
Transp lantat ion  
During follow-up periods (median, 870 days; range, 
126-2913 days), 51 patients (61%) relapsed or had a pro- 
gressive disease (Table 2). Both relapse rates as well as time 
to relapse after autologous transplantation were very similar 
among patients with and without ES (Table 3). The relapse 
rate was 61% in both groups, and the median time to 
relapse was 365 versus 367 days, respectively. The relapse 
rates were similar regardless of disease stage. However, 
there was a difference between the 2 groups in the sites and 
patterns of relapse. Relapse occurred in visceral organs in 
17 (85%) of 20 patients who had ES versus 15 (48%) of 
31 patients without ES (P = .01). There was no difference in 
survival rates for patients with ES who did (n = 23) or did 
not (n = tl)  receive steroid therapy (52% versus 38%, P = 
.84). The only patients receiving high-dose and long-term 
steroids were those with pulmonary diffuse alveolar hemor- 
rhage, and they were long-term survivors. 
Table 3. Relapse Rates in Breast Cancer Patients With and Without 
Engraftment Syndrome (ES) 
No. With Relapse/No. of Patients (%) 
Disease Stage With ES Without ES p* 
ii t/3 (33) I/8 (I 2) .42 
Ill 2/9 (22) 9/28 (32) .57 
IV 17/21 (8 I) 21/24 (87) .54 
Total 20/33 (61 ) 31/51 (61 ) NS 
*Statistical nalysis was performed using the Fisher exact test o com- 
pare the relapse rates of 2 groups of patients (with ES versus without ES). 
Ef fec t  o f  ES on  D isease-Re la ted  Mor ta l i ty  
The mortality and SUlMval rates were found to be differ- 
ent in the 2 groups (patients with ES versus patients without 
ES). At the time of this analysis, 17 (52%) of 33 ES patients 
had died compared with only 16 (31%) of 51 patients without 
ES (Table 4, F@are 1). Although this difference in mortality 
rate is dear, it has not reached statistical significance (P = .08). 
Analysis of the data of the patients who had relapsed 
after autologous transplantation showed that the patients 
with a history of ES had significantly worse prognoses. As 
mentioned above (Table 2), a total of 51 patients (61%) had 
relapsed. Of those patients, 20 had histories of ES and 
17 (85%) of 20 have died due to disease progression, 
whereas 16 (51%) of the other 31 patients who had no his- 
tory of ES died due to disease progression (P = .008) (Fig- 
ure 2). Univariate analysis howed that in addition to ES, 
stage of disease at transplantation, remission status at trans- 
plantation (complete versus partial remission), number of 
prior treatments, and visceral relapse were associated to a 
variable degree with increased mortality rates, whereas 
estrogen/progesterone receptor positivity was associated 
with better prognoses (Table 5). In multivariate analysis, ES 
was independently associated with increased mortality (P = 
.04; hazard ratio, 2.1; 95% confidence interval, 1.002-4.62) 
when analyzed in association with number of prior treat- 
ments and progesterone r ceptor status (Table 6). 
DISCUSSION 
ES or autoaggression syndrome described after autologous 
BMT/PBSCT was proposed to be a GVHD-like syndrome. 
ES manifests mainly with skin rash (with biopsy findings consis- 
Table 4. Difference inMo'rtali~y Rates in Breast Cancer Patients With 
Engraftment Syndrome CES) Compared With Patients Without ES 
Mortality, No. of Patients Who Died/No. of Patients (%) 
Disease Stage Overall With ES Without ES P* 
Stage II 1/11 (9) I/3 (33) 0/8 (0) .08 
Stage III 8/28 (29) 2/9 (22) 6/I 9 (32) .60 
Stage IV 24/45 (53) 19/21 (67) 10/24 (42) .09 
Total 33/84 (39) 17/33 (52) 16/51 (31) .08 
*Statistical nalysis was performed using the Fisher exact est to 
compare the mortality rates of 2 groups of patients (with ES versus 
without ES). 
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F igure  I .  Kaplan-Meier curves howing the difference insurvival rates of patients who developed engraftment syndrome (ES) after transplantation 
(n = 33; broken line) versus patients who did not develop ES after transplantation (n = 51; solid line). 
tent with acute GVHD),  noninfectious fever, and, in some 
patients, diarrhea, platelet ransfusion refractoriness, and pul- 
monary alveolar hemorrhage [18-21]. ES was reported to 
respond to steroid treatment. Although the pathogenesis of ES 
is not known, it has been hypothesized that mechanisms that 
normally safeguard the self-tolerance properties of the immune 
system are suppressed by high-dose chemotherapy. Hence, dur- 
ing early stages of engraftment, autoreactive effector T cells 
may be present in excess quantities under uninhibited condi- 
tions, leading to the various manifestations of this syndrome 
[18,22]. It has been observed that patients with breast cancer 
are at higher risk of developing ES compared to lymphoma 
patients and that such a difference could be attributed to an 
immune system that is likely to be less suppressed in breast 
cancer patients [18]. Because of the possible analogy of ES to 
acute GVHD, we investigated any evidence for GVT effect 
among breast cancer patients who developed ES versus those 
who did not. In this analysis, we folmd a 39% ES incidence rate 
mnong 84 patients undergoing autografting. There was no dif- 
ference in rdapse rates (approximately 61%) for patients with or 
without ES, with median follow-up of 871 days. This finding 
raises the issue of antologous GVHD and its effectiveness in
mediating antimmor esponse and reducing the high relapse 
rates seen after autografting [11]. Because breast cancer cells 
express major histocompatibility-complex class II antigens 
[23,24J, studies aiming at inducing autologous GVHD after 
autografting in breast cancer patients have been described. 
Cyclosporin, interferon (* and 7, and interleukin 2 have been 
used in various combinations toinduce autologous GVHD [15- 
17,25,26]. The results of these studies and others done m other 
diseases have failed to show any significant improvement in
relapse or survival rates, despite the induction of histologically 
proven skin GVHD in high proportions of the patients tud- 
ied. Thus, the results of our analysis are in agreement with the 
results of those studies, suggesting no significant GVT effect of this 
GVHD-like ES. Other than the clinical symptoms, the only evi- 
dence suggesting that ES is like GVHD is found in pathological 
results of skin biopsies that are consistent with GVHD [I 8]. 
The  most significant, and unexpected, results of our 
present study are the findings that relapsed patients who 
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had developed engraftment syndrome (ES) (n = 20; broken line) or not (n = 31; solid line). 
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Table 5. Effects of Various Prognostic" Factors on Mortality in Breast Cam'er 
Patients (Univariate Analysis) 
Hazard 95% Confidence 
Prognostic Factor P Ratio Interval 
Engraftment syndrome .089 1.809 0.914-3.582 
Disease stage .0058 2.945 1.367-6.346 
Remission status .0015 3.238 1.568-6.688 
No. of prior treatments .0053 2.762 1.353-5,637 
Estrogen receptor positive .0706 0,505 0.241 - 1.059 
Progesterone receptor positive .031 I 0.417 0.189-0.924 
Visceral relapse .0835 1.980 0.914-4.291 
had ES after autografting had more widespread (80% vis- 
ceral) aggressive disease resulting in significantly higher 
mortality rates (85%) and shorter median survival times 
(586 days) compared with those who did not develop ES 
(48% and 847 days, respectively; P = .01). The reason for 
such differences i most likely not related to disease stage or 
behavior, because the trend for poorer outcomes in patients 
with ES has been observed in patients with advanced as well 
as less advanced isease during the time of transplantation. 
Conversely, ES might indicate widely micrometastatic dis- 
ease at the time of transplantation, and, therefore, ES may 
be a manifestation of the immune response against an exist- 
ing residual tumor. Although such an explanation is highly 
speculative, multivariate analysis has shown that the occur- 
rence of ES is an independent prognostic factor for bad 
outcome after autografting in our breast cancer patient 
population. Until the exact pathophysiology of ES is eluci- 
dated, it will be difficult to explain such grim outcomes for 
those breast cancer patients. Another theoretical reason for 
the difference in survival rates after relapse could be differ- 
ences in the treatment of relapse used in each group (with 
ES versus without ES). Although this issue was not studied 
here, most patients were treated with standard chemo- 
therapy and/or radiotherapy by their referring physicians, 
so it is more likely that the extent of disease rather than the 
treatment contributed to the difference in survival. 
In summary, we report a high incidence of ES with no 
effect on relapse rate in breast cancer patients undergoing 
autologous transplantation. In addition, those patients 
who develop ES have higher mortality rates and signifi- 
cantly shorter survival times than patients who do not 
develop ES, and thus ES may be a marker for high-risk 
groups of breast cancer patients that should be the target 
of further evaluation and treatment after autografting. 
Although these observations are intriguing, further valida- 
Table 6. Engraftment Syndrome asa Predictive Factor for Mortality in 
Breast Cancer Patients Undergoing Autologous Transplantation 
~nltivariate Analyis) 
Hazard 95% Confidence 
Prognostic Factor P Ratio Interval 
Engraftment syndrome .0494 2.152 
No. of prior treatments .0005 4.418 
Progesterone receptor status .0051 0.300 
1.002-4.62 I 
1.909-10.225 
0.129-0.697 
tion in larger studies or studies from other centers will be 
important before firm conclusions can be reached. 
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